Vijaya Diagnostic Centre has appointed Mr. Narasimha Raju K.A. as its Chief Financial Officer effective July 09, 2026, to strengthen its financial management and governance standards. The Board of Directors approved the appointment during a meeting held on July 09, 2026, in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The meeting commenced at 17:30 hrs and concluded at 17:40 hrs.

Mr. Narasimha Raju K.A. is a Chartered Accountant with over 20 years of experience in finance, accounting, corporate governance, and strategic leadership. His background includes working with S R Batliboi & Co, an affiliate of Ernst & Young, and senior leadership roles in healthcare, diagnostics, renewable energy, and real estate sectors. He previously served as the CFO of Vijaya Diagnostic Centre from March 15, 2021, to March 26, 2025, leading strategic initiatives including the company's initial public offering (IPO) during the COVID-19 pandemic.

Prior to rejoining, he served as the CFO of Yashoda Group of Hospitals. His expertise includes investor relations, mergers and acquisitions, financial reporting under Ind AS and IFRS, and regulatory compliance. The detailed disclosure regarding the appointment is provided in the table below:

abrdn Asia Limited, acting on behalf of funds advised and managed by the group, reduced its shareholding in Vijaya Diagnostic Centre Limited through an open market sale on June 29, 2026. The transaction involved the disposal of 133,199 equity shares, resulting in a decrease of the acquirer's voting rights by 0.1294%. This regulatory filing was submitted under Regulation 29(2) of the Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Prior to the sale, the acquirer held 3,464,245 shares, representing 3.3667% of the total share capital. The shares were held across various funds within the Aberdeen Group, including the Aberdeen Group plc Segregated Fund, Aberdeen India Fund, Inc., and Aberdeen Asia Focus plc. Registered holders for these securities included entities such as Pictet & Cie - Switzerland, State Street Bank & Trust, and BNP Paribas Securities Services.

The disposal was executed entirely through the open market mode. As a result of the transaction, the total holding of abrdn Asia Limited and its Persons Acting in Concert (PAC) now stands at 3,331,046 shares. This revised holding constitutes 3.2373% of the total voting capital of Vijaya Diagnostic Centre Limited. The equity share capital of the company remains unchanged at Rs. 102,896,728, based on a par value of Rs 1.

The filing confirms that the acquirer does not belong to the promoter or promoter group of the target company. The shares of Vijaya Diagnostic Centre Limited are listed on BSE Limited and the National Stock Exchange of India Ltd. The disclosure was signed by Jenny Clarke, an authorised signatory for abrdn Asia Limited, in Edinburgh on June 30, 2026.

Shareholding Details

The following table outlines the changes in the acquirer's shareholding: